IMR Press / EJGO / Volume 24 / Issue 6 / pii/2003228

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Immunohistochemical expression of glucose transporter Glut 1 and cyclin D1 in breast carcinomas with negatine lymph nodes

Show Less
1 Department of Pathology, University Hospital of Patras, Rion, Greece
2 Department of Obstetrics and Gynaecology, University Hospital of Patras, Rion, Greece
Eur. J. Gynaecol. Oncol. 2003, 24(6), 544–546;
Published: 10 December 2003

All malignant cells appear to have increased needs for glucose in vitro as well as in vivo. The enhanced glucose uptake is medi­ated through transporters (Gluts), whose action and expression are regulated by oncogenes and growth factors. Cyclin Dl is a nuclear protein that plays an important role in regulating the cell cycle by promoting entry of cells from the G 1 to S phase. Increased expression of Glut1 glucose transporter and cyclin Dl have been reported in several neoplasms. In the present study we examined the expression of Glut1 and cyclin Dl in breast carcinomas with negative lymph nodes. We studied 78 infiltrating ductal carcinomas (25 grade 1, 36 grade 2, and 17 grade 3) with negative lymph nodes. Glut1 was expressed in 28% of grade 1, 63.8% of grade 2 and 58.7% of grade 3 carcinomas. Nuclear expression of cyclin Dl was detected in 32% of grade 1, 44.4% of grade 2, and 41.2% of grade 3 carcinomas. From our study it appears that in breast carcinomas with negative lymph nodes Glut 1 expression is better cor­related to the grade of the neoplasm than cyclin Dl.

Glucose transporter
Cyclin D1
Breast cancer
Back to top